In TNBC, SNHG22 drives tumor progression by sponging miR-324-3p and upregulating SUDS382; LRRC75A-AS1 (SNHG29) promotes tumor progression by targeting the miR-380-3p/BAALC pathway [35,147], and SNHG8 promotes tumor progression through the miR-335-5p/PYGO2 axis [112]. Here, SNHG8 is linked to neoplasm.